DexTech Medical AB (XSAT:DEX) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:DEX DexTech Medical AB XSAT:DEX
19 GF Score
Price kr9.96
! 3 Warning Signs
View Full Analysis

What is DexTech Medical AB 5-Year Yield-on-Cost %?

DexTech Medical AB XSAT:DEX -4.23% 19 5-Year Yield-on-Cost % is 0.00 as of Jul. 22, 2026. GuruFocus rates XSAT:DEX with a GF Score™ of 19/100. The stock has 3 warning signs investors should review. Among 152 Biotechnology companies, DexTech Medical AB ranks worse than 657894.08% on this metric.

DexTech Medical AB's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for DexTech Medical AB's 5-Year Yield-on-Cost % or its related term are showing as below:



XSAT:DEX's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.68
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

DexTech Medical AB  (XSAT:DEX) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


DexTech Medical AB 5-Year Yield-on-Cost % Related Terms


XSAT:DEX vs VRTX, REGN, ALNY: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, DexTech Medical AB's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DexTech Medical AB 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DexTech Medical AB's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where DexTech Medical AB's 5-Year Yield-on-Cost % falls into.


XSAT:DEX
19GF Score
DexTech Medical AB XSAT:DEX
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexTech Medical AB 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of DexTech Medical AB is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
DexTech Medical AB (XSAT:DEX) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 22, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on DexTech Medical AB and its competitors. According to the industry distribution chart, DexTech Medical AB ranks #999999 out of 152 companies in the Biotechnology industry.
Is DexTech Medical AB's 5-Year Yield-on-Cost % too high?
DexTech Medical AB's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, DexTech Medical AB ranks #999999 out of 152 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, DexTech Medical AB has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does DexTech Medical AB's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DexTech Medical AB ranks #999999 out of 152 companies for 5-Year Yield-on-Cost %. This places DexTech Medical AB in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.68, based on 152 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on DexTech Medical AB and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DexTech Medical AB's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexTech Medical AB stock overvalued right now?
DexTech Medical AB (XSAT:DEX) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. DexTech Medical AB's overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For DexTech Medical AB (XSAT:DEX), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DexTech Medical AB Business Description

Address Dag Hammarskjolds Vag 34A, Uppsala, SWE, 752 37
DexTech Medical AB is a Swedish research company specializing in drug development for urological oncology, with a prominent focus on prostate cancer. The company develops drug candidates using a proprietary carbohydrate platform, advancing treatments aimed at castration-resistant prostate cancer and related conditions. Its operations center on research, development, and licensing of these drug candidates. It has four drug candidates: OsteoDex, SomaDex, PSMA-binding conjugates, and GuaDex.
19GF Score

Get the complete analysis for XSAT:DEX

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr9.96
Price